Mobile Health App Intervention in Reducing the Side Effects of Androgen Deprivation Therapy in Patients with Prostate Cancer

Inclusion Criteria

• Participants must have owned a smartphone for > 1 year (Phase I)
• Participants must be English-speaking (Phase I)
• Staff members from Dana-Farber Cancer Institute, Department of Medical Oncology, or Brigham and Women’s Hospital, Department of Surgery (Phase I)
• Patients with prostate cancer. No specific timeframe after prostate cancer diagnosis will be required for these patients. No limitations regarding their disease characteristics will be imposed (e.g. metastatic disease) (Phase I)
• Patients may or may not be currently receiving treatment (Phase I)
• Men diagnosed with prostate cancer presenting to Dana-Farber/Brigham and Women’s Hospital Cancer Center (DF/BWHCC) and about to initiate androgen deprivation therapy (ADT) for the first time will be considered (Phase II)
• The ability to walk 400 m, medical clearance from their primary physician (Phase II)
• English speaking (Phase II)
• Cognitively alert and literate (Phase II)
• Ability to read or hear with or without contacts/glass and hearing aid (Phase II)
• Ownership of a smartphone for > 1 yr (Phase II)
• Men who have been under a rigorous structured exercise regime, such as individuals who engage in more than 900 minutes of moderate physical activity per week in the last 6 months will not be considered. Moderate physical activity is defined as a total energy expenditure of > 2000 calories daily (Phase II)
• Men who have already started their treatment with ADT will not be eligible (Phase II)

Exclusion Criteria

• Subordinates to the principal investigator (PI) (here, Dr. Trinh) will not be eligible as this may potentially result in coercion (Phase I)
• Post-ADT treatment, planned systemic chemotherapy, planned treatment with abiraterone or enzalutamide, bone metastases, acute illness, any musculoskeletal, cardiovascular, or neurologic disorders that could inhibit or put them at risk from exercising (Phase II)